Teladoc Health (TDOC)
(Delayed Data from NYSE)
$8.75 USD
-0.43 (-4.68%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.77 +0.02 (0.23%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.75 USD
-0.43 (-4.68%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.77 +0.02 (0.23%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Zacks News
Bulls & Bears Battle It Out In Big Tech
by Daniel Laboe
Yields are on the rise and valuation-propelled tech is getting deflated.
Bull of the Day: Align Technology, Inc. (ALGN)
by Benjamin Rains
Align Technology, Inc. (ALGN) is a new-age dental company, best known for its Invisalign system. The tech-focused firm posted back-to-back strong quarters to end 2020 on a high note and its outlook is impressive...
Stock Market News for Feb 26, 2021
by Zacks Equity Research
U.S. stock markets closed sharply lower on Thursday as rising bond yields raised concerns among market participants on risky assets like equities
Teladoc (TDOC) Q4 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings result reflects revenue gains, more than offset by flared-up expenses.
Case Shiller Home Prices Rose Better-Than-Expected In December
by Zacks Equity Research
Case Shiller Home Prices Rose Better-Than-Expected In December
Nasdaq Still Down as Rotation Continues, Home Depot Beats
by Mark Vickery
As we rotate back toward a more "normal" economy -- less dependent on "stay at home" activities -- we were bound to see some profit-taking with some of these biggest names of the pandemic.
5 Stocks That Make Ark Innovation ETF (ARKK) Red Hot
by Sweta Killa
ARKK is centered around the idea of disruptive innovation, which is defined as the introduction of a technologically-enabled new product or service that potentially changes the way the world works.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $287.86, marking a -1.15% move from the previous day.
Earnings Preview: Teladoc (TDOC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $290.43 in the latest trading session, marking a +0.67% move from the prior day.
What's in the Offing for Centene (CNC) This Earnings Season?
by Zacks Equity Research
Centene's (CNC) Q4 results are likely to reflect escalating costs and other COVID-related factors.
Teladoc (TDOC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $263.83 in the latest trading session, marking a +0.38% move from the prior day.
What's in the Cards for HCA Healthcare (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have witnessed better patient volumes and improved revenues.
Is Teladoc Health (TDOC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TDOC) Outperforming Other Medical Stocks This Year?
Higher Testing to Aid Quest Diagnostics' (DGX) Q4 Earnings
by Zacks Equity Research
Within non-COVID base business, Quest Diagnostics (DGX) is expected to have secured higher returns in Q4 from the acquisitions of MACL, Memorial Hermann Outreach and Blueprint Genetics.
Anthem (ANTM) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results benefit from higher revenues stemming from robust Medicaid and Medicare businesses, partly offset by higher costs.
Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings
by Zacks Equity Research
Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.
Thermo Fisher (TMO) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher's (TMO) Life-Science Solutions and Specialty Diagnostics segments are expected to have contributed, banking on COVID-19-led growing healthcare needs.
Anthem (ANTM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem (ANTM) is likely to have witnessed increased revenues and a rise in membership during Q4, offset by an escalating expense level.
Here's Why You Should Add Teladoc (TDOC) to Your Portfolio
by Zacks Equity Research
Teladoc (TDOC) has been benefiting from strong revenues, higher telehealth visits and robust cash balance.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $245.50, moving -0.5% from the previous trading session.
UnitedHealth (UNH) Q4 Earnings Top Estimates, Revenues up Y/Y
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results benefit from higher revenues and return of healthcare utilization to normalcy level, partly offset by higher costs.
Demand for COVID-19 Tests to Drive Abbott (ABT) Q4 Earnings
by Zacks Equity Research
Within EPD, Abbott (ABT) is expected to have witnessed visible signs of rebound through Q4.
New Coronavirus Strain to Keep Telehealth Stocks in Demand
by Sapna Bagaria
Telemedicine is here to stay as the new coronavirus strain triggers a fear psychosis at large, thereby retaining solid demand for telehealth stocks.
Teladoc (TDOC) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $225.25 in the latest trading session, marking a -0.13% move from the prior day.